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Introduction
Delayed-release dimethyl fumarate (DMF) is an oral 
treatment for patients with relapsing–remitting multi-
ple sclerosis (RRMS).1,2 In two 2-year pivotal phase 3 
trials (DEFINE and CONFIRM) in patients with 
RRMS, DMF significantly reduced clinical and mag-
netic resonance imaging (MRI) activity and demon-
strated an acceptable safety profile.3,4 ENDORSE is 
an ongoing 12-year extension of DEFINE/CONFIRM 
designed to evaluate the long-term efficacy and safety 
of DMF. We report a 5-year interim analysis (2 years 
DEFINE/CONFIRM; 3 years ENDORSE) of clinical 
and MRI outcomes and safety from ENDORSE. This 
report focuses on data for DMF 240 mg twice daily 
(BID; the approved dosage); however, data for all 
treatment groups are presented in figures or tables.
Methods
Patients and study design
In DEFINE/CONFIRM, eligible patients were of age 
18–55 years, had a diagnosis of RRMS,5 an Expanded 
Long-term effects of delayed-release dimethyl 
fumarate in multiple sclerosis: Interim analysis 
of ENDORSE, a randomized extension study
Ralf Gold, Douglas L Arnold, Amit Bar-Or, Michael Hutchinson, Ludwig Kappos, 
Eva Havrdova, David G MacManus, Tarek A Yousry, Carlo Pozzilli, Krysztof Selmaj, 
Marianne T Sweetser, Ray Zhang, Minhua Yang, James Potts, Mark Novas, David H Miller, 
Nuwan C Kurukulasuriya, Robert J Fox and Theodore J Phillips
Abstract
Background: Delayed-release dimethyl fumarate (DMF) demonstrated strong efficacy and a favorable 
benefit–risk profile for patients with relapsing–remitting multiple sclerosis (RRMS) in phase 3 DEFINE/
CONFIRM studies. ENDORSE is an ongoing long-term extension of DEFINE/CONFIRM.
Objective: We report efficacy and safety results of a 5-year interim analysis of ENDORSE (2 years 
DEFINE/CONFIRM; minimum 3 years ENDORSE).
Methods: In ENDORSE, patients randomized to DMF 240 mg twice (BID) or thrice daily (TID) in 
DEFINE/CONFIRM continued this dosage, and those initially randomized to placebo (PBO) or glat-
iramer acetate (GA) were re-randomized to DMF 240 mg BID or TID.
Results: For patients continuing DMF BID (BID/BID), annualized relapse rates were 0.202, 0.163, 0.139, 
0.143, and 0.138 (years 1–5, respectively) and 63%, 73%, and 88% were free of new or enlarging T2 
hyperintense lesions, new T1 hypointense lesions, and gadolinium-enhanced lesions, respectively, at year 
5. Adverse events (AEs; serious adverse events (SAEs)) were reported in 91% (22%; BID/BID), 95% 
(24%; PBO/BID), and 88% (16%; GA/BID) of the patients. One case of progressive multifocal leukoen-
cephalopathy was reported in the setting of severe, prolonged lymphopenia.
Conclusion: Treatment with DMF was associated with continuously low clinical and magnetic resonance 
imaging (MRI) disease activity in patients with RRMS. These interim data demonstrate a sustained treat-
ment benefit and an acceptable safety profile with DMF.
Keywords: Relapsing–remitting multiple sclerosis, delayed-release dimethyl fumarate (DMF), Expanded 
Disability Status Scale, ENDORSE, DEFINE
Date received: 16 December 2015; revised: 21 March 2016; accepted: 30 March 2016
Correspondence to: 
R Gold  
Department of Neurology, 
St. Josef Hospital, Ruhr 
University Bochum, 
Gudrunstr 56, Bochum 
44791, Germany. 
ralf.gold@rub.de
Ralf Gold  
Department of Neurology, 
St. Josef Hospital, Ruhr 
University Bochum, Bochum, 
Germany
Douglas L Arnold  
NeuroRx Research, Montreal, 
QC, Canada/Montreal 
Neurological Institute, 
McGill University, Montreal, 
QC, Canada
Amit Bar-Or  
Montreal Neurological 
Institute, McGill University, 
Montreal, QC, Canada
Michael Hutchinson  
St. Vincent’s University 
Hospital, Dublin, Ireland
Ludwig Kappos  
Department of Neurology, 
University Hospital of Basel, 
Basel, Switzerland
Eva Havrdova  
Department of Neurology, 
First Faculty of Medicine, 
Charles University in Prague, 
Prague, Czech Republic
David G MacManus  
Tarek A Yousry  
David H Miller  
NMR Research Unit, Queen 
Square Multiple Sclerosis 
Centre, University College 
London (UCL) Institute of 
Neurology, London, UK
Carlo Pozzilli  
Department of Neurology 
and Psychiatry, Sapienza 
University of Rome, Rome, 
Italy
Krysztof Selmaj  
Medical University of Lodz, 
Lodz, Poland
Marianne T Sweetser  
Mark Novas 
Biogen, Cambridge, MA, 
USA
649037MSJ0010.1177/1352458516649037Multiple Sclerosis JournalR Gold, DL Arnold
research-article2016
Original Research Paper
 by guest on May 20, 2016msj.sagepub.comDownloaded from 
Multiple Sclerosis Journal 
2 http://msj.sagepub.com
Disability Status Scale (EDSS)6 score of 0–5.0, and 
⩾1 relapse within 1 year before randomization or ⩾1 
gadolinium-enhanced (Gd+) lesion 0–6 weeks before 
randomization. Key exclusion criteria included 
relapse or corticosteroid treatment within 50 days 
before randomization or prior treatment with glati-
ramer acetate (GA) within 3 months before randomi-
zation (DEFINE) or at any time (CONFIRM). Patients 
were randomized to DMF 240 mg BID or thrice daily 
(TID) or placebo (PBO; 1:1:1 in DEFINE) or daily 
GA 20 mg (1:1:1:1 in CONFIRM) for 96 weeks.3,4
ENDORSE enables up to 14 years of follow-up 
(2 years DEFINE/CONFIRM + 12-year extension; 
Figure 1). Originally designed as a multicenter, rand-
omized, dose-blind, dose-comparison study, patients 
who received DMF 240 mg BID or TID in either par-
ent study remained on the same dosage in ENDORSE. 
Patients who received PBO or GA were randomized 
1:1 to DMF 240 mg BID or TID. After initiation of 
ENDORSE, DMF was approved for RRMS in several 
countries at 240 mg BID. A protocol amendment 
(approved March 2014) outlines a second, open-label 
phase (beyond year 5), in which all participants receiv-
ing DMF 240 mg TID are switched to BID dosing.
ENDORSE enrolled eligible patients who completed 
DEFINE/CONFIRM, excluding those who experi-
enced significant changes in medical history, with-
drew consent; discontinued study treatment; or if 
alanine transaminase (ALT), aspartate aminotrans-
ferase (AST), or gamma-glutamyl transpeptidase 
increased to >3 times the upper limit of normal 
(ULN). The final (week 96) visit of DEFINE/
CONFIRM served as the baseline for ENDORSE; 
patients were followed every 4 weeks for 24 weeks 
and every 12 weeks thereafter for up to 12 years.
Efficacy assessments
The primary efficacy endpoint was the proportion of 
patients relapsed at 2 years (DEFINE) and annualized 
relapse rate (ARR) at 2 years (CONFIRM). Additional 
endpoints included time to 12-week sustained disabil-
ity progression and number of new T1 hypointense 
lesions (T1), new or enlarging T2 hyperintense lesions 
(T2), and Gd+ lesions at 2 years. Relapse (confirmed 
by an Independent Neurologic Evaluation Committee) 
was defined as new or recurrent neurologic symptoms 
lasting ⩾24 hours, accompanied by new objective 
neurologic findings.
Figure 1. Design of ENDORSE extension study (phase 1).
BID: twice daily; DMF: dimethyl fumarate; GA: glatiramer acetate; PBO: placebo; PO: by mouth; QD: once daily; SC: subcutaneous; 
TID: thrice daily.
aDMF: delayed-release DMF.
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Secondary objectives of ENDORSE include assess-
ment of long-term ARR, proportion of patients 
relapsed, disability progression (measured every 
6 months by EDSS), and MRI assessments of brain 
lesions. Patients at sites with validated MRI capabil-
ity were eligible to participate in the MRI portion of 
DEFINE/CONFIRM and could continue in the MRI 
cohort at the same ENDORSE site.3,4 MRI scans 
were performed yearly for each patient by the same 
reading center as that of the parent study. MRI end-
points included number of T1, T2, and Gd+ lesions 
and percentage of patients free of these lesions. 
Normalized brain volume was determined at base-
line of DEFINE/CONFIRM and ENDORSE, and 
percent brain volume change (PBVC) was calculated 
automatically for each post-baseline MRI visit rela-
tive to baseline.
Safety assessments
The primary objective of ENDORSE was evaluation 
of long-term safety of DMF in patients with RRMS. 
Adverse events (AEs) and concomitant medications 
were monitored and recorded continuously. Laboratory 
assessments were performed on a schedule: blood 
chemistry and urinalysis at baseline, every 4 weeks 
until week 24, and every 12 weeks thereafter and 
hematological parameters at baseline and every 
12 weeks for up to 12 years. On initiation of the 
amended protocol, the frequency of some study proce-
dures was decreased to every 24 weeks; however, 
patients continued visits every 12 weeks for drug dis-
pensing and vital signs assessment.
Patients who completed or discontinued DMF and 
had a lymphocyte count less than the lower limit of 
normal (LLN) were followed at least every 12 weeks 
until lymphocyte counts recovered or until 48 weeks 
after the last dose (whichever came sooner). 
Unscheduled relapse assessment was performed as 
necessary.
Statistical analysis
This 5-year interim analysis (data cutoff date: 14 May 
2014) included patients who received ⩾1 dose of 
DMF in ENDORSE. Results are summarized through-
out DEFINE/CONFIRM (years 1–2) and ENDORSE 
(years 3–5). Data are presented according to treatment 
received in the parent or extension study: continuing 
DMF (BID/BID and TID/TID) and new to DMF 
(PBO/BID, PBO/TID, GA/BID, and GA/TID). To 
increase sample size in the brain atrophy analysis, 
DMF BID/TID dosing was pooled from the groups 
new to DMF.
A Poisson or negative binomial regression model was 
used to analyze ARR. The proportion of patients 
relapsed or with progression was estimated based on 
the Kaplan–Meier product limit method. Disability 
progression was defined as ⩾1.0-point increase in 
EDSS from baseline EDSS = 1.0 sustained for 
24 weeks or ⩾1.5-point increase in EDSS from base-
line EDSS = 0 sustained for 24 weeks. Numbers of T1 
and T2 lesions were analyzed by negative binomial 
regression model, adjusted for region and lesion vol-
ume at DEFINE/CONFIRM baseline. Number of 
Gd+ lesions was analyzed by logit regression.
Comparisons of brain atrophy between BID/BID and 
PBO/DMF and GA/DMF were based on the analysis 
of covariance of ranked data, adjusted for DEFINE/
CONFIRM or ENDORSE baseline number of Gd+ 
lesions and T2 lesion volume.
No sample size was calculated for ENDORSE; num-
ber of eligible patients was determined by the number 
of DEFINE/CONFIRM participants.
Safety parameters were tabulated according to the 
treatment received during parent study or extension 
phase 1, continuing DMF (BID/BID and TID/TID) and 
new to DMF (PBO/BID, PBO/TID, GA/BID, and GA/
TID), and summarized using descriptive statistics.
Standard protocol approvals, registrations, and 
patient consents
The study was approved by central and local ethics 
committees and conducted in accordance with 
International Conference on Harmonization Guidelines 
for Good Clinical Practice and the Declaration of 
Helsinki. All patients provided written informed 
consent.
Results
Efficacy data are described below for the DMF BID 
dosage and reported for DMF TID in tables or figures; 
safety data for both dosages are summarized below.
Patients
Of 2651 patients randomized and dosed in DEFINE/
CONFIRM, 2079 completed these studies and 1736 
were enrolled and dosed in ENDORSE (intention-
to-treat (ITT) population): BID/BID, n = 501; TID/
TID, n = 502; PBO/BID, n = 249; PBO/TID, n = 248; 
GA/BID, n = 118; and GA/TID, n = 118. As of 
14 May 2014, total follow-up for this 5-year interim 
analysis was 4981 patient-years. Follow-up of patients 
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continuing and new to DMF was 3058 and 1923 
patient-years, respectively. For BID/BID patients 
remaining on study (n = 364), minimum follow-up 
was ~5 years. Among patients new to DMF BID in 
ENDORSE, minimum follow-up for those remaining 
on study (n = 163) was ~3 years (Supplementary Table 
e-1). Of the DEFINE/CONFIRM MRI cohort 
(n = 1221), 746 were treated in ENDORSE: 363 
received DMF BID and 383 DMF TID. Patient dis-
position is presented in Figure 2. Baseline demo-
graphic and disease characteristics at the start of 
DEFINE/CONFIRM were generally well balanced 
across treatment groups and were similar between the 
ENDORSE ITT population (Table 1) and MRI cohort 
(Supplementary Table e-2).
Efficacy
Relapses. Cumulative ARR for ENDORSE BID/BID 
patients during years 0–5 was 0.163 (95% confidence 
interval (95% CI): 0.140, 0.190; Figure 3(a) presents 
ARRs by yearly interval), and the estimated propor-
tion relapsed at 5 years was 40.1% (95% CI: 35.9%, 
44.7%; Figure 3(b)).
Cumulative ARR for ENDORSE PBO/BID patients 
during years 0–5 was 0.240 (95% CI: 0.196, 0.296). 
Improvements were generally observed following the 
switch from PBO to DMF after year 2 (Figure 3(a)). 
The estimated proportion of PBO/BID patients 
relapsed at 5 years was 51.5% (95% CI: 45.2%, 
58.1%; Figure 3(b)).
Cumulative ARR for ENDORSE GA/BID patients 
during years 0–5 was 0.199 (95% CI: 0.148, 0.269; 
Figure 3(a) presents data by yearly interval), and the 
estimated proportion relapsed at 5 years was 42.1% 
(95% CI: 33.5%, 52.0%; Figure 3(b)).
Disability progression. An estimated 18.6% (95% CI: 
15.3%, 22.4%) of ENDORSE BID/BID patients had 
confirmed 24-week EDSS progression after 5 years 
(Figure 3(c)). For PBO/BID patients, the estimated 
proportion with disability progression after 5 years 
was 21.1% (95% CI: 16.2%, 27.1%; Figure 3(c)); for 
GA/BID patients, the corresponding proportion was 
25.7% (95% CI: 18.4%, 35.2%; Figure 3(c)).
MRI outcomes
Patients continuing DMF in ENDORSE. Among 
ENDORSE BID/BID patients, 73% and 63% were free 
of T1 and T2 lesions, respectively, during years 4–5; 
88% were free of Gd+ lesions (year 5 scan). For BID/
BID patients, adjusted mean number of T1 and T2 
lesions during years 4–5 was 0.5 (95% CI: 0.3, 0.7) 
and 1.2 (95% CI: 0.8, 1.8), respectively (Figure 4(a) 
and (b)); mean (±standard error (SE)) number of Gd+ 
lesions at year 5 was 0.2 ± 0.05 (Figure 4(c)).
Patients new to DMF in ENDORSE. Of 
ENDORSE PBO/BID patients, 85% and 68% were free 
of T1 and T2 lesions, respectively, during years 4–5; 
82% were free of Gd+ lesions (year 5 scan). For PBO/
BID patients, adjusted mean number of T1 and T2 
hyperintense lesions during years 4–5 was 0.2 (95% 
CI: 0.1, 0.5) and 0.8 (95% CI: 0.4, 1.5), respectively 
(Figure 4(a) and (b)); mean (±SE) number of Gd+ 
lesions at year 5 was 0.2 ± 0.06 (Figure 4(c)).
Of ENDORSE GA/BID patients, 64% and 62% were 
free of T1 and T2 lesions, respectively, during years 
4–5 and 86% were free of Gd+ lesions (year 5 scan). 
For GA/BID patients, adjusted mean number of T1 
and T2 lesions during years 4–5 was 0.7 (95% CI: 0.3, 
1.7) and 1.6 (95% CI: 0.7, 3.8), respectively, and 
mean (±SE) number of Gd+ lesions at year 5 was 
0.6 ± 0.48.
Brain atrophy. At year 2 of DEFINE/CONFIRM, 
among patients in ENDORSE, adjusted PBVC from 
baseline was significantly lower with DMF BID ver-
sus PBO (p = 0.0070); in post hoc exploratory analy-
ses, significantly lower PBVC was observed versus 
GA (p = 0.0035; Table 2). Adjusted PBVC relative to 
ENDORSE baseline at years 3, 4, and 5 was not sig-
nificantly different in BID/BID patients compared 
with the PBO/DMF or GA/DMF groups (Table 2). 
Annualized rate of adjusted mean PBVC calculated 
throughout 5 years of follow-up was −0.32 per year 
(95% CI: −0.37, −0.27)) in BID/BID patients, compa-
rable with that of healthy volunteers.7
Safety. The overall incidence of AEs, serious AEs 
(SAEs), and discontinuations due to AEs (Supple-
mentary Table e-3) was similar among the treatment 
groups who continued DMF from DEFINE/CONFIRM 
and those new to DMF; however, a higher proportion 
of patients new to DMF discontinued due to AEs, 
largely from flushing and gastrointestinal (GI) events 
that tend to occur early in DMF therapy.3,4,8 The most 
common individual AEs and SAEs are summarized in 
Table 3. Multiple sclerosis (MS) relapse and naso-
pharyngitis were most common in patients continuing 
DMF. Flushing and GI-related events were more 
common among patients new to DMF, with inci-
dences highest during the first year of ENDORSE 
(Supplementary Figure e-1) and generally consistent 
with those of DMF-treated patients in the parent stud-
ies, wherein incidences were highest during the first 
month and decreased substantially thereafter.3,4,8 
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Table 1. Baseline demographics of the ITT population in ENDORSE and at start of DEFINE and CONFIRM.
Characteristica Continued DMFb New to DMF
BID/BID 
(n = 501)
TID/TID 
(n = 502)c
PBO/BID 
(n = 249)
PBO/TID 
(n = 248)
GA/BID 
(n = 118)
GA/TID 
(n = 118)
Start of ENDORSE
 Age (years) 39.7 (9.1) 40.0 (9.1) 39.9 (8.8) 40.5 (9.4) 38.2 (8.5) 39.5 (9.5)
 Age < 40 years, n (%) 237 (47) 233 (46) 119 (48) 114 (46) 68 (58) 56 (47)
 Female, n (%) 352 (70) 354 (71) 178 (71) 166 (67) 86 (73) 76 (64)
 White, n (%) 403 (80) 413 (82) 202 (81) 198 (80) 98 (83) 103 (87)
 Weight (kg), mean (SD) 70.6 (17.8) 71.8 (17.0) 70.8 (16.6) 73.8 (16.9) 73.4 (21.5) 72.0 (17.9)
 Time since first MS symptoms (years) 10.0 (6.5) 9.3 (6.1) 10.1 (6.7) 9.5 (6.2) 9.0 (5.8) 9.2 (6.3)
 Time since diagnosis of MS (years) 6.9 (5.0) 6.4 (4.9) 6.8 (5.3) 7.0 (5.4) 6.2 (5.0) 6.3 (4.8)
  Alternative RRMS treatment in prior study,d 
n (%)
13 (3) 10 (2) 24 (10) 13 (5) 8 (7) 6 (5)
Start of DEFINE and CONFIRM
 Relapses in prior year 1.3 (0.7) 1.3 (0.7) 1.3 (0.8) 1.4 (0.8) 1.3 (0.6) 1.4 (0.6)
 EDSS score 2.5 (1.3) 2.4 (1.1) 2.5 (1.1) 2.5 (1.2) 2.6 (1.2) 2.7 (1.2)
BID: twice daily; DMF: dimethyl fumarate; EDSS: Expanded Disability Status Scale; GA: glatiramer acetate; ITT: intention-to-treat; MS: multiple sclerosis; 
PBO: placebo; RRMS: relapsing–remitting multiple sclerosis; SD: standard deviation; TID: thrice daily.
aValues are mean (SD) unless otherwise stated.
bDMF: delayed-release DMF.
c One patient randomized to DMF TID took GA throughout the CONFIRM study. This patient was counted in the TID/TID group of the ITT population and in 
the GA/TID group of the safety population in ENDORSE.
dInterferon β-1a.
Although the study was not designed to assess the 
duration of each GI or flushing episode in a precise 
manner, AE duration was summarized based on the 
investigator-reported onset and resolution dates. 
There were no apparent differences in the duration of 
flushing or GI-related AEs across the treatment 
groups based on the available investigator-reported 
data. Overall, the median (25%, 75% percentile) dura-
tion of flushing and related symptoms (n = 689 events 
out of 466 patients who had any events) was 80 days 
(7, 716 days), and the median duration of GI-related 
events (n = 1011 events out of 523 patients who had 
any events) was 12 days (4, 71 days).
The incidence of individual AEs leading to treatment 
discontinuation was ⩽1%–4% (Supplementary Table 
e-4). Of patients new to DMF, AEs leading to treat-
ment discontinuation were generally related to flush-
ing and GI tolerability; the majority of discontinuations 
occurred during the first 6 months of treatment 
(Supplementary Table e-3), consistent with observa-
tions in DEFINE/CONFIRM.3,4
The most commonly reported ENDORSE SAE was 
MS relapse, with other SAEs occurring in ⩽5 patients 
in any treatment group (Table 3). Incidence of serious 
infections was ⩽4% in any treatment group 
(Supplementary Table e-3). A total of 27 malignancies 
occurred in 18 patients continuing DMF and 8 new to 
DMF; overall incidence of malignancies was 2% for 
patients who continued DMF (Supplementary Table 
e-5). No increased risk of malignancy was observed 
among DMF-treated patients compared with cancer 
rates reported for the general MS population (4% 
summary estimate (95% CI: 3%, 6%)).9
Hematological findings in ENDORSE were consist-
ent with those from DEFINE/CONFIRM. Patients 
new to DMF had decreases in mean white blood cell 
(WBC) and lymphocyte counts, whereas these values 
remained stable with no further overall decrease in 
patients continuing DMF. The incidence of lympho-
cyte counts <0.5 × 109/L was 7%–8% of the patients 
continuing DMF and 6%–9% of those new to DMF. 
There was no overall increased risk of serious oppor-
tunistic infections; however, subsequent to the data 
cutoff for this report, a fatal case of progressive mul-
tifocal leukoencephalopathy (PML) in a patient 
treated with DMF 240 mg TID was reported in the set-
ting of severe, prolonged lymphopenia (~290–580 
cells/mL3 over 3.5 years); full details of this case are 
reported separately.10
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Figure 3. (a) ARR by yearly interval, (b) time to first relapse, and (c) time to disability progression by EDSS (24-week 
confirmation): DEFINE, CONFIRM, and ENDORSE integrated analysis (ENDORSE ITT population).  
(a) Adjusted ARR and 95% CI based on negative binomial regression, adjusted for baseline EDSS score (⩽2.0 vs >2.0), 
baseline age (<40 vs ⩾40 years), region, and number of relapses in the 1 year prior to entry into DEFINE or CONFIRM. 
Data after patients switched to alternative MS medications during the period are excluded. (b) Only objective relapses 
are included in the Kaplan–Meier estimate analysis; patients who did not experience a relapse prior to switching to 
alternative MS medications or withdrawal from study are censored at the time of switch or withdrawal. (c) Patients were 
censored if they withdrew from study or switched to alternative MS medication without a progression.
ARR: annualized relapse rate; BID: twice daily; CI: confidence interval; EDSS: Expanded Disability Status Scale; GA: glatiramer 
acetate; ITT: intention-to-treat; MS: multiple sclerosis; PBO: placebo; TID: thrice daily.
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Hepatic AEs or SAEs occurred in ⩽3% or <1% of the 
patients, respectively, in any treatment group. Few 
patients (⩽3%) continuing DMF had ALT or AST 
levels ⩾3 × ULN, and no case fulfilled Hy’s law crite-
ria for drug-induced liver injury. The incidence of 
transaminase elevations in ENDORSE is consistent 
with observations in DEFINE/CONFIRM, wherein 
incidences were similar between the DMF- and PBO-
treated groups.3,4
In DEFINE/CONFIRM, 19% of the patients receiv-
ing DMF BID and 18% of the PBO-treated patients 
Figure 4. (a) Number of new or enlarging T2 hyperintense lesions by yearly interval, (b) number of new nonenhancing 
T1 hypointense lesions by yearly interval, and (c) mean number of Gd+ lesions by yearly interval: DEFINE, CONFIRM, 
and ENDORSE analysis (MRI cohort).
BID: twice daily; CI: confidence interval; GA: glatiramer acetate; Gd+: gadolinium-enhanced; MRI: magnetic resonance image; PBO: 
placebo; TID: thrice daily.
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experienced renal or urinary AEs. Renal or urinary 
events were reported in 23%, 20%, and 13% of 
ENDORSE BID/BID, PBO/BID, and GA/BID 
patients, respectively. For BID/BID patients, the most 
common renal or urinary AEs (⩾3% occurrence in all 
treatment groups) were proteinuria (7%), microalbu-
minuria (6%), and hematuria (5%). Renal or urinary 
AEs resulted in discontinuation in ⩽1% of any treat-
ment group, and serious renal or urinary AEs occurred 
in <1% of any treatment group.
Discussion
DMF is an oral agent indicated for the treatment of 
relapsing forms of MS.11 The availability of agents 
with novel mechanisms of action affords practitioners 
a wider array of options to treat RRMS and increases 
opportunities to individualize therapy for patients 
intolerant of, or suboptimally responsive to, other 
therapies. This is particularly germane to MS, the het-
erogeneous nature of which contributes to variability 
in therapeutic response.12,13 Additionally, oral agents 
afford convenience of administration. Efficacy must 
always be carefully weighed against risk of AEs, par-
ticularly throughout longer treatment periods.14–17
In this first phase of ENDORSE, low clinical and 
MRI activity was sustained during 5 years of DMF 
treatment. Patients initially randomized to PBO or 
Table 2. Percent brain volume change.
ENDORSE MRI cohort of DEFINE and CONFIRM
 DMFa BID PBO GA
Year 1
 N 197 179 88
 Mean (SD) −0.42 (0.747) −0.39 (0.684) −0.62 (0.704)
 Median −0.34 −0.33 −0.71
 p-value vs BID/BIDb − 0.8961 0.0464
Year 2
 n 189 158 79
 Mean (SD) −0.83 (0.962) −0.94 (0.906) −1.15 (0.784)
 Median −0.68 −0.81 −1.09
 p-value vs BID/BIDb − 0.0070 0.0035
ENDORSE MRI cohort assessed from ENDORSE baseline
 BID/BID PBO/DMFa GA/DMFa
Year 3 (year 1 of ENDORSE)
 n 163 127 78
 Mean (SD) −0.45 (0.669) −0.52 (0.708) −0.42 (0.858)
 Median −0.35 −0.41 −0.28
 p-value vs BID/BIDc − 0.6955 0.2216
Year 4 (year 2 of ENDORSE)
 n 148 120 63
 Mean (SD) −0.61 (0.809) −0.85 (0.981) −0.80 (1.008)
 Median −0.61 −0.68 −0.61
 p-value vs BID/BIDc − 0.2189 0.6346
Year 5 (year 3 of ENDORSE)
 n 129 103 57
 Mean (SD) −0.85 (0.958) −1.19 (1.252) −1.07 (1.272)
 Median −0.86 −0.96 −1.00
 p-value vs BID/BIDc − 0.1678 0.5001
BID: twice daily; DMF: dimethyl fumarate; GA: glatiramer acetate; Gd+: gadolinium-enhanced; PBO: placebo; SD: standard devia-
tion; MRI: magnetic resonance image.
aDelayed-release DMF.
bBased on rank model, adjusted for DEFINE/CONFIRM baseline Gd+ lesion count and T2 lesion volume.
cBased on rank model, adjusted for ENDORSE baseline Gd+ lesion count and T2 lesion volume.
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GA in DEFINE/CONFIRM demonstrated improve-
ments after switching to DMF in ENDORSE; how-
ever, with no control group, the relative impact of 
changes in the natural course of MS in ENDORSE 
cannot be assessed. In addition, as with other long-
term extension studies,17,18 bias could result because 
not all patients randomized in the parent study were 
enrolled and dosed in ENDORSE.
The recommended dosage for DMF is 240 mg BID. 
Data for 240 mg TID were included to explore the 
general consistency of between-dose effects. In this 
interim analysis, effect sizes with DMF BID and TID 
were broadly similar; however, ENDORSE was not 
powered to analyze dose-dependent differences.
MRI is valuable for diagnosis, prognosis, and assess-
ment of treatment response in patients with MS.19 
Continued DMF treatment resulted in a low frequency 
of new non-enhancing T1 hypointense lesions, new or 
enlarging T2 hyperintense lesions, and Gd+ lesions 
over 5 years. Reduced MRI disease activity was also 
noted in patients who switched to DMF in ENDORSE.
There was a short delay in treatment initiation in 
ENDORSE introduced during re-randomization; 
therefore, some patients who switched from PBO or 
GA received DMF later than continuously treated 
patients in the extension (mean treatment gap of 
19 days for continuous BID vs 42–65 days for switch-
ers (MRI cohort)).
Accelerated loss of brain tissue in MS correlates 
with cognitive impairment and worse EDSS and 
quality of life.20–23 Annual rates of brain volume loss 
in patients treated continuously with DMF were low 
and comparable with rates in healthy volunteers.7 
This analysis suggests a continuous beneficial effect 
Table 3. Most common AEs (incidence ⩾10% in any treatment group) and serious AEs (incidence ⩾3 patients in any 
treatment group).
Event, n (%)a Continued DMFb New to DMFb
BID/BID 
(n = 501)
TID/TID 
(n = 501)
PBO/BID 
(n = 249)
PBO/TID 
(n = 248)
GA/BID 
(n = 118)
GA/TID 
(n = 119)
Any AE 454 (91) 459 (92) 237 (95) 231 (93) 104 (88) 101 (85)
 MS relapse 149 (30) 170 (34) 70 (28) 67 (27) 28 (24) 31 (26)
 Nasopharyngitis 124 (25) 121 (24) 45 (18) 45 (18) 18 (15) 17 (14)
 Flushing 52 (10) 64 (13) 76 (31) 59 (24) 26 (22) 25 (21)
 Urinary tract infection 93 (19) 78 (16) 35 (14) 36 (15) 17 (14) 10 (8)
 Headache 73 (15) 61 (12) 31 (12) 27 (11) 12 (10) 10 (8)
  Upper respiratory 
tract infection
72 (14) 66 (13) 32 (13) 31 (13) 8 (7) 9 (8)
 Diarrhea 45 (9) 38 (8) 39 (16) 36 (15) 11 (9) 12 (10)
 Back pain 48 (10) 60 (12) 24 (10) 26 (10) 11 (9) 3 (3)
 Fatigue 40 (8) 46 (9) 26 (10) 24 (10) 5 (4) 6 (5)
 Bronchitis 34 (7) 49 (10) 19 (8) 18 (7) 8 (7) 5 (4)
 Proteinuria 36 (7) 36 (7) 19 (8) 29 (12) 5 (4) 7 (6)
 Abdominal pain upper 18 (4) 27 (5) 30 (12) 29 (12) 10 (8) 12 (10)
 ALT increased 14 (3) 21 (4) 17 (7) 19 (8) 12 (10) 8 (7)
Any SAE 109 (22) 124 (25) 59 (24) 40 (16) 19 (16) 23 (19)
 MS relapse 50 (10) 58 (12) 23 (9) 19 (8) 8 (7) 10 (8)
 Urinary tract infection 5 (<1)   0   0 3 (1) 1 (<1)   0
 Breast cancer 3 (<1) 3 (<1)   0   0   0 2 (2)
 Gastritis 2 (<1)   0   0 3 (1)   0   0
 Fall 3 (<1) 2 (<1) 1 (<1)   0 1 (<1)   0
 Uterine leiomyoma   0 1 (<1) 3 (1)   0   0   0
 Traffic accident 1 (<1) 3 (<1) 1 (<1) 1 (<1) 1 (<1)   0
AE: adverse event; ALT: alanine aminotransferase; BID: twice daily; DMF: dimethyl fumarate; GA: glatiramer acetate; MS: multiple 
sclerosis; PBO: placebo; TID: thrice daily.
Safety population is based on received treatment.
a AE incidence represents cumulative incidence throughout the observation period; SAE incidence represents cumulative incidence 
throughout the entire observation period (parent and extension studies).
bDMF: delayed-release DMF.
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of DMF on brain atrophy and a higher impact of 
early versus delayed treatment. DMF demonstrated 
improved beneficial effects versus GA; however, 
statistical significance must be interpreted cau-
tiously given the post hoc, exploratory nature of the 
comparison. Other disease-modifying MS therapies 
appear to slow brain atrophy rates;15,24,25 however, 
comparisons are difficult due to differing study 
designs, imaging techniques, and analysis methodol-
ogy across clinical trials.
DMF treatment was associated with relatively low 
relapse rates, disability progression, and frequency of 
new MRI lesions over 5 years. Cumulative outcomes 
generally favored patients receiving continuous ver-
sus delayed DMF treatment, although clinical and 
neuroradiological improvements were observed fol-
lowing switch to DMF.
The safety profile observed in ENDORSE appears 
compatible with long-term use of DMF and is compara-
ble with that of DEFINE/CONFIRM.3,4 Generally, sim-
ilar incidences of AEs, AEs leading to discontinuation, 
and SAEs were observed among patients continuing 
DMF from the parent studies and those new to DMF.
Patients new to DMF had decreases in mean WBC and 
lymphocyte counts consistent with those of DMF-
treated patients in DEFINE/CONFIRM. In patients 
continuing DMF, mean WBC and lymphocyte counts 
remained stable throughout time, and no further overall 
decrease in mean values was observed compared with 
the parent studies. In a post hoc analysis of DEFINE/
CONFIRM; the clinical efficacy of DMF was not sub-
stantially different between patients with and without 
absolute lymphocyte counts less than the LLN.26
Subsequent to the data cutoff for this report, a case of 
PML in a patient treated with DMF TID was reported 
in the setting of severe, prolonged lymphopenia.10 
Rare cases of PML also occurred in the post-market-
ing setting in the presence of prolonged lymphopenia 
(two cases in the presence of severe lymphopenia 
(approximately <500 mm3) and one case in the pres-
ence of moderate (nadir 600 mm3) lymphopenia, each 
persisting >6 months). Aside from these rare cases 
of PML, no overall increased risk of serious infec-
tions was noted, including other opportunistic infec-
tions. Analyses of data from phase 2 or phase 3 or 
ENDORSE studies support the importance of lym-
phocyte monitoring to identify patients experiencing 
lymphopenia persisting ⩾6 months.26 Per recent labe-
ling changes in the United States, a recent complete 
blood cell count (CBC), including lymphocytes, 
should be available before initiation of DMF, with 
retesting recommended after 6 months of treatment, 
every 6–12 months thereafter, and as clinically indi-
cated.11 Similarly, the European Medicines Agency 
(EMA) recommends obtaining a CBC before start 
of treatment and every 3 months during treatment.27 
Interruption of DMF should be considered for 
patients with lymphocyte counts <500/mm3 persist-
ing for >6 months. Lymphocyte counts should be 
followed until recovery.
In ENDORSE, flushing, nasopharyngitis, and GI 
events were among the most commonly reported AEs. 
Flushing and GI events were more common among 
patients new to DMF in ENDORSE, particularly dur-
ing the first year of treatment, consistent with the 
parent studies.28 Although preliminary data on AE 
duration are reported, it should be noted that the stud-
ies were not designed to examine AE duration as an 
endpoint, particularly duration of episodic events, and 
there was a lack of temporal precision in reporting; 
results of the duration analyses should be interpreted 
cautiously. Phase 4 MANAGE study results of DMF 
in RRMS also indicate that GI-related events were 
generally transient and manageable.29
The overall benefit–risk profile of DMF remains 
favorable. The sustained clinical and neuroradiologi-
cal efficacy and AE profile observed in this interim 
analysis further support DMF as a valuable long-term 
treatment option for patients with RRMS.
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